GLP-1 dosing gaps and appetite rebound: what the data says

What did @msmartine.e actually say?

The short version: she missed her GLP-1 injection by about a week, traveled, ate less carefully, moved less, and gained six pounds. She weighed in at 131 pounds and noticed her appetite had returned noticeably during the extended gap. Her conclusion was simple: the drug was doing more work than she realized, and skipping it had consequences.

She was upfront about the specifics. "I haven't taken my GLP in about three and a half weeks," she said, adding that her appetite was "in full swing" during that period. She also acknowledged poor hydration, minimal movement, and more snacking than usual. She framed the whole thing as an accountability check, not a medical explainer. That framing matters when evaluating what she actually claimed versus what her audience might take away from it.

Does the science back this up?

Yes, mostly. The return of appetite after stopping or delaying a GLP-1 medication is well-documented, not anecdotal. The mechanism is real.

GLP-1 receptor agonists like semaglutide work partly by slowing gastric emptying and acting on hypothalamic hunger signals. When you stop taking them, those effects wear off. How fast depends on the drug's half-life. Semaglutide, which is weekly-dosed, has a half-life of roughly seven days, meaning meaningful pharmacological activity declines significantly after about two to three weeks off drug. Wilding et al. (2022, New England Journal of Medicine) found that participants who stopped semaglutide after 68 weeks regained about two-thirds of their lost weight within one year. Appetite returned as a primary driver. A 21-day gap would push most users past the point where therapeutic levels are meaningfully maintained, especially for weekly formulations.

The six-pound gain over roughly five weeks is also biologically plausible given increased caloric intake, reduced activity, and the loss of appetite suppression. It is not alarming on its own, but it is not meaningless either.

What did they get wrong (or right)?

She got the core experience right. The appetite returning after a prolonged gap is not a placebo effect or bad willpower. It is pharmacology. Credit where it is due: she did not blame herself entirely, and she did not catastrophize the weight regain.

What she glossed over is more interesting. She said "my clothes don't fit different, I don't feel different," which is worth scrutinizing. A six-pound change in a few weeks, especially after reintroducing suppressed appetite, could reflect fluid retention and glycogen resynthesis as much as fat mass. She is not a clinician, so this is not a serious error, but it is worth noting that scale weight after a period of dietary change is a noisy signal.

She also said her appetite was "extremely suppressed" the morning after resuming her injection. That is physiologically fast for most long-acting formulations. Peak suppression typically takes more than one dose to reestablish. This may reflect expectation effects or individual variation rather than full drug action from a single dose. Davies et al. (2021, Lancet) noted that appetite suppression with semaglutide generally builds over several weeks of consistent dosing.

What should you actually know?

If you are on a weekly GLP-1 medication, missing three weeks is not just a scheduling inconvenience. It is a meaningful gap in drug exposure that will, for most people, result in partial or full return of baseline hunger signals. The drug is not fixing a broken behavior. It is altering a hormonal environment. When the drug leaves, that environment shifts back.

The weight regain data is unambiguous here. The STEP 1 trial extension (Wilding et al., 2022, NEJM) was one of the clearest demonstrations that GLP-1 medications require ongoing use to maintain their effects. This is not a character flaw in the user. It is the pharmacology of the drug class.

What this video does well is model honest self-reporting. She did not hide the gain, did not blame the medication, and did not claim she was doing everything perfectly. That kind of transparency is genuinely useful in a community where social comparison pressure runs high. What it does not do is explain the mechanism, which means viewers may come away thinking the lesson is just "don't skip your shot" without understanding why the gap creates the effect it does.

For anyone in maintenance dosing, the clinical conversation worth having with your prescriber is about what "maintenance" actually means for your specific formulation and dose, and what the plan is for travel or disrupted schedules. That is a prescriber conversation, not a TikTok one.